As a growing number of countries move towards legal regulation for non-medical cannabis, governments are pushing the boundaries of the three UN drug control treaties. At the 61st session of the Commission on Narcotic Drugs (CND), TNI co-organised a side event to explore the issue, addressing the various challenges and opportunities involved.
In a historic vote, the United Nations (UN) has finally recognised the medicinal value of cannabis.
A group of prominent drug policy organisations has welcomed the move, but also expressed disappointment that this reform does not go far enough, as cannabis remains categorised internationally alongside drugs like heroin and cocaine.
The review was revisiting cannabis scheduling decisions made in the 1950s, which were driven by prevailing racist and colonial attitudes, and not based on scientific evaluations. This has remained unchallenged.
As a growing number of countries move towards legal regulation for non-medical cannabis, governments are pushing the boundaries of the three UN drug control treaties. At the 61st session of the Commission on Narcotic Drugs (CND), TNI will co-organise a side event to explore the issue, addressing the various challenges and opportunities involved.
A top Russian diplomat, Yuri V. Fedotov, has emerged as the front-runner in the race to become the Executive Director of the UN Office on Drugs and Crime (UNODC) – the world's new drug czar, according to Colum Lynch, a longtime Washington Post correspondent who reports on the United Nations for Turtle Bay.
A strong attack against the European practice of 'leniency' regarding cannabis use and possession took place at the United Nations Commission on Narcotic Drugs (CND) session (11-15 March, 2002) in Vienna. There was an orchestrated attempt to pass a CND resolution to put a dam against the 'leniency'.
At the Commission on Narcotic Drugs (CND) in March 2008 in Vienna three resolutions on cannabis were tabled. They were all clearly against 'lenient policies' in some countries depenalising or decriminalizing the use of cannabis. One of the resolutions called for the criminalization of drug abuse that would have significantly expanded the UN drug conventions.
The issue of harm reduction continues to be controversial during the negotiations in Vienna for the Political Declaration that has to be adopted in March 2009 at the High Level Segment of the Commission on Narcotic Drugs (CND). There is severe pressure on delegates to drop their insistence on incorporating the language and principles of harm reduction in the political declaration, or to accept some watered down version.
In response to the 2007 annual report of the International Narcotics Control Board (INCB), which called on countries to 'abolish or prohibit coca leaf chewing and the manufacture of coca tea', President Evo Morales of Bolivia sent a letter to the Secretary General of the United Nations, Ban Ki-Moon to express profound concern and discontent with the INCB in relation to the coca leaf, the practice of chewing it and the other traditional uses that have 3,000 years of history and are fully legally recognised in Bolivia.
The UN Commission considers to bring ketamine under the control of the 1971 Convention on Psychotropic Substances contrary to WHO recommendations. The 58th Session of the UN Commission on Narcotic Drugs (CND) in March 2015 has been asked to consider a Chinese proposal to place ketamine – an essential medicine used for anaesthesia – in Schedule I of the 1971 Convention (E/CN.7/2015/7 and E/CN.7/2015/81). Ketamine is the only available anaesthetic for essential surgery in most rural areas of developing countries, home to more than 2 billion of the world’s people. Scheduling ketamine under any of the 1971 treaty schedules will reduce its availability and further deepen the already acute crisis of global surgery.
Allan Clear of the Harm Reduction Coalition made an urgent appeal on the Obama White House to intervene in the current negotiations about the Political Declaration on the 1998 UNGASS review that has to be adopted in March 2009 at the High Level Segment of the Commission on Narcotic Drugs (CND). For more than two million people living with HIV, mainly in Africa, hopes are high for a change in Obama's foreign policy.
A useful overview of UN endorsement of harm reduction measures; the legality of harm reduction services under the Drug Conventions; the obligation in human rights law to ensure access to harm reduction services and the global state of harm reduction, listing 82 countries and territories worldwide that presently support or tolerate harm reduction.
The following statement by Abdellatif Adebibe of the Moroccan Confederation of Associations for the Development of the Senhaja Rif Region, was due to be screened as a civil society contribution to a discussion on alternative development and development-oriented drug policy at an intersessional meeting of the Commission on Narcotic Drugs in Vienna. Abdellatif represented cannabis farmers at UNGASS 2016, following the meeting of the Global Forum of Producers of Prohibited Plants in Heemskerk, the Netherlands, organised by TNI.
Just over one year away from the 2016 UNGASS, denying the reality that the drug policy landscape has fundamentally changed and that tensions with the UN drug conventions are occuring, is no longer a credible option. Secretary General Ban Ki-moon urged member states to use the 2016 UNGASS on drugs "to conduct a wide-ranging and open debate that considers all options." TNI calls for a special advisory group that should be tasked with recommending how to better deal with the contentious issues following the 2016 UNGASS, in preparation for the next UN high-level review in 2019.
The Lancet - On April 19–21, 2016, the UN General Assembly Special Session on Drugs (UNGASS) will convene to chart a course for the future to tackle the world's drugs problem. The 2016 UNGASS represents a rare opportunity to reassess the global approach to drugs and to move towards drug policies that more effectively address the three UN pillars of peace and security, human development, and human rights. We believe that we need a new consensus that includes a commitment to revise the range of indicators used to assess and improve drug policy effectiveness.